INSIGHTS ON DRUG DEVELOPMENT

  • Vaccine Development: Strategic Approach & Response During Pandemics

    Over the past decade, outbreaks of H1N1 influenza, Sars-Cov, Ebola, and MERS have sparked ongoing conversations about strategic approaches and responses to pandemics and epidemics. Now with the spread of SARS-CoV-2 intensifying, scientists, together with pharmaceutical companies, are reinventing the approach of how to bring these life-saving drugs to market faster without impacting product quality, safety, or efficacy.

  • The End Of End Point Assays: How SPR Is Changing Analytics In Vaccine Design And Development

    Discover how SPR can be used to accelerate vaccine discovery and development by helping overcome analytical challenges that have plagued the industry for decades.

  • Successful Techniques For Progressing Biotherapeutic Candidates From Late Discovery To The Clinic

    The reality is that many initially promising biotherapeutic candidates never make it to commercialization. It is estimated that only 1 in 1000 preclinical candidates reach the commercial market. Why does this happen? There are many that fail due to lack of efficacy or safety, but there are also candidates that fail due to stability, aggregation, and other issues related to cell line or process issues. In our latest white paper, we help you to prepare for a successful transition to bring your drug candidate from discovery to the clinic.

  • Overcoming Development And Manufacturing Challenges For Biologic Therapies

    Whether rapidly scaling manufacturing capabilities, shortening supply chains, accelerating the availability of emerging therapies, or reducing the risk of a pharmaceutical shortage, the pharmaceutical manufacturing platform can make all the difference in the success or failure of a biologic therapy.

DRUG DEVELOPMENT SOLUTIONS

  • Quick To Clinic For Biologics: Fact Sheet

    The pressure to file an IND makes accelerated Phase I safety testing a priority. With the Quick to Clinic program, Thermo Fisher Scientific can deliver your large molecule drug substance for First-in-Human studies in as little as 12 months. Now you can meet important milestones – such as filing the IND – or secure additional funding with all the confidence your project needs and, we can supply. Because helping you reduce the time it takes to get your discovery to the patients who need it matters, our Quick to Clinic for Biologics is made with speed and flexibility.

  • Particle Control In Biopharmaceuticals

    Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

  • HyClone Cell Boost 3 Supplement

    Improve productivity and cell growth in fed-batch cultures by supplementing the cell culture medium to boost nutrients depleted during culture. HyClone™ Cell Boost™ 3 Supplement provides nutrients such as amino acids, glucose, and trace elements that are suitable for research and bioprocessing applications.

  • Crystallization And Solid State Chemistry Fact Sheet

    Understanding the physical characteristics of API and required modification is critical to successful product development and product performance. Across a global network, Thermo Fisher Scientific integrate small molecule API, solid form science and drug product development to produce formulation enabling API to speed your product development to the next milestone.

  • Fill/Finish Services For Viral Vectors

    We offer services for new and emerging, mid-size, and large biopharmaceutical companies and research institutions developing viral vectors and viral vaccines who need Fill / Finish capacity. Our solutions are flexible, comprehensive Fill / Finish services for viral vectors that comply with current regulatory and quality requirements.